



Notices of Application - 2001

[Federal Register: October 11, 2001 (Volume 66, Number 197)]
[DEPARTMENT OF JUSTICE]

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Application

Pursuant to §1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on February 6, 2001, Lifepoint, Inc., 1205 S. Dupont Street, Ontario, California 91761, made application by renewal to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the basic classes of controlled substances listed below:

Drug	Schedule
Tetrahydrocannabinols (7370)	I
3,4-Methylenedioxymphetamine (7400)	I
3,4-Methylenedioxy-N-ethylamphetamine (7404)	I
3,4-Methylenedioxy-N-methylamphetamine (7405)	I
Amphetamine (1100)	II
Methamphetamine (1105)	II
Phencyclidine (7471)	II
Benzoylcegonine (9180)	II
Morphine (9300)	II

The firm plans to use gram quantities of the listed controlled substances to manufacture drug abuse test kits. Any other such applicant and any person who is presently registered with DEA to manufacture such substance may file comments or objections to the issuance of the proposed registration.

Any such comments or objections may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, DC 20537, Attention: DEA Federal Register Representative (CCF), and must be filed no later than December 10, 2001.

Dated: October 2, 2001. Laura M. Nagel,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 01-25445 Filed 10-10-01; 8:45 am]
BILLING CODE 4410-09-M

An Interesting Side Note

Are you aware that the General Conference Corporation purchased a pharmaceutical-laboratory for 2.5 million dollars called LifePoint Inc., of course with sacred money, tithes and offerings [please see page 21]? This corporation is certified by the DEA to carry cocaine, marijuana, and other illegal drugs [please see page 22]. LifePoint Inc. makes portable drug-testing kits for different agencies, particularly law-enforcement. And as always, the laity is left in the dark.

How can any Christian organization with one ounce of dignity participate in and profit monetarily from the prosecution of intemperate people by selling illegal drug testing kits to law enforcement agencies? And at the same time lobby the US House of Congress to enforce laws on temperance.

Is that not a conflict of interest when you profit from *intemperance* and lobby for *temperance*? How noble it must be that these men are bringing us down to new lows in Adventism. "Woe unto you, scribes and Pharisees, hypocrites! For ye are like unto whited sepulchers, which indeed appear beautiful outward, but are within full of dead men's bones, and of all uncleanness. Even so ye also outwardly appear righteous unto men, but within ye are full of hypocrisy and iniquity." Matthew 23:27-28.

Is it just a coincidence that the purchase of LifePoint Inc., as far as I know, was never mentioned in any of the numerous church communications? By the way, LifePoint Inc. is listed on the American Stock Exchange under the stock quote "LFP." On a side note, their stock is not doing well at all, but as long as people keep sending in their tithes, LifePoint Inc. will survive, which should be good news to their stock shareholders.

SCHEDULE 14A
(RULE 14A-101)

P.5 - 10-7
p.10 - 19-16

INFORMATION REQUIRED IN PROXY STATEMENT

SCHEDULE 14A INFORMATION
PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE
SECURITIES EXCHANGE ACT OF 1934

<Table>

Filed by the registrant ☒ [X]

Filed by a party other than the registrant ☐ []

Check the appropriate box:

☐ [] Preliminary proxy statement

☐ [] Confidential, for use of the Commission
only (as permitted by Rule 14a-6(e)(2))

☒ [X] Definitive proxy statement

☐ [] Definitive additional materials

☐ [] Soliciting material pursuant to Rule 14a-11(c) or 14a-12

</Table>

LIFEPOINT, INC.

(Name of Registrant as Specified in Its Charter)

LIFEPOINT, INC.

(Name of Person(s) Filing Proxy Statement)

Payment of filing fee (Check the appropriate box):

☒ [X] No fee required.

☐ [] Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and
0-11.

(1) Title of each class of securities to which transaction applies:

(2) Aggregate number of securities to which transaction applies:

(3) Per unit price or other underlying value of transaction computed
pursuant to Exchange Act Rule 0-11:

(4) Proposed maximum aggregate value of transaction:

(5) Total fee paid:

☐ [] Fee paid previously with preliminary materials.

☐ [] Check box if any part of the fee is offset as provided by Exchange Act
Rule 0-11(a)(2) and identify the filing for which the offsetting fee
was paid previously. Identify the previous filing by registration
statement number, or the form or schedule and the date of its filing.

(1) Amount previously paid:

(2) Form, schedule or registration statement no.:

states, where he developed a new direct sales business model that directly resulted in an 18% revenue increase per month and played a crucial role in taking the company public in August of 1999. Prior to Headhunter.net, Mr. Canfield held several senior marketing and sales positions at IDEXX Laboratories, the market leader in veterinary diagnostic and services. While at IDEXX, Mr. Canfield was instrumental in the rapid growth of the organization and dramatically increased market share, which more than doubled revenues. Earlier in his career, Mr. Canfield held various general management, and senior operations and sales positions at Baxter Healthcare. Mr. Canfield worked at Abbott Laboratories prior to Baxter, and held positions of increasing sales responsibility. Mr. Canfield received a Bachelor of Science in Industrial Technology from Southern Illinois University.

Michele A. Clark has more than 25 years of accounting and finance experience in manufacturing and high tech companies. She became an employee of the Company on April 12, 1999 and was formally elected as its Controller and appointed as its Chief Accounting Officer on April 16, 1999. Ms. Clark was formally, prior to joining the Company, the Controller at Auto-Graphics, Inc. ("Auto-Graphics"), a software development company, where she managed all accounting, finance, human resource and administrative functions within the company. Additionally, she was responsible for all filings with the Commission and shareholder relations. Prior to Auto-Graphics, Ms. Clark was Controller at Typecraft, Inc. ("Typecraft"), a commercial lithographer, where she was responsible for all accounting, finance and human resource functions. Prior to Typecraft, Ms. Clark served as accounting manager for three retail companies with multiple locations. Ms. Clark graduated Cum Laude with a B.S. in Accounting from the University of La Verne.

COMPLIANCE WITH SECTION 16(a) OF THE EXCHANGE ACT

Based solely on a review of Forms 3 and 4 furnished to the Company under Rule 16a-3(e) promulgated under the Exchange Act, with respect to fiscal 2001, the Company is not aware of any director or executive officer of the Company who failed to file on a timely basis, as disclosed in such forms, reports required by Section 16(a) of the Exchange Act.

7

10

As of March 31, 2001, i.e., the end of fiscal 2000, Jonathan J. Pallin, a former director of the Company, and the General Conference Corporation of Seventh-day Adventists (the "GCC") were the only beneficial owners of 10% or more of the Common Stock known to the Company. Both Mr. Pallin and the GCC have advised the Company that they made timely filings with respect to their transactions in fiscal 2001.

CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

On September 10, 1997, Substance Abuse Technologies, Inc. ("SAT"), the then parent of the Company, filed a petition for reorganization under the Federal Bankruptcy Code, which reorganization proceeding was successfully completed on May 26, 1998. However, in September 1997, the then three directors of the Company including Linda H. Masterson (who currently is the Chairman of the Board, President and Chief Executive Officer of the Company), who were also directors of SAT, decided, at the request of Ms. Masterson, to resolve the Company's financial problems at that time outside the bankruptcy court and, accordingly, no petition in bankruptcy was filed for the Company. The Company subsequently successfully raised funds to continue the development of the product being commercialized and has significantly increased stockholder value during the past three years.

On October 29, 1997, with the approval of its bankruptcy court, SAT sold its controlling stockholder interest in the Company (i.e., 5,575,306 shares or 76.4% of the 7,297,206 then outstanding shares of the Common Stock) to Meadow Lane Partners, LLC ("Meadow Lane"), which action, together with the subsequent resignations of two directors who served on both boards of directors, terminated SAT's relationship as the parent of the Company. On November 4, 1997, Ms. Masterson resigned as a director of SAT, thereby severing the last of the relationships between SAT and the Company.

See the section "Employment and Severance Agreements" under this caption "Management" for information relating to the Company's severance agreement with Linda H. Masterson, the Chairman of the Board, the President, the Chief Executive Officer and a director of the Company.

On October 10, 1999 (as modified by the Board on April 5, 2000 and the

SYMBOL	CRSP TOTAL RETURNS INDEX FOR:	04/2000	09/2000	08/2001
-----	-----	-----	-----	-----
-----	- LifePoint, Inc.	100.0	140.8	94.7
- - - - -	+ Nasdaq Stock Market (US Companies)	100.0	99.2	49.6
-----	++ NASDAQ Stocks (SIC 3840 - 3849 US + Foreign)	100.0	128.5	83.8
	Surgical, Medical, and Dental Instruments and Supplies			

</Table>

Notes:

- The lines represent monthly index levels derived from compounded daily returns that include all dividends.
- The indexes are reweighted daily, using the market capitalization on the previous trading day.
- If the monthly interval, based on the fiscal year-end, is not a trading day, the preceding trading day is used.
- The index level for all series was set to \$100.0 on 14/19/2000.

Prepared by CRSP (www.crsp.uchicago.edu), Center for Research in Security Prices, Graduate School of Business, The University of Chicago. Used with permission. All rights reserved.

(C)Copyright 2001

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

The following table sets forth, as of the Record Date, certain information with respect to (1) any person known to the Company who beneficially owned more than 5% of the Common Stock, (2) each director of the Company, one of whom is a nominee for election at the Meeting, (3) the Chief Executive Officer of the Company and (4) all directors and executive officers as a group. Each beneficial owner who is a natural person

16

19

has advised the Company that he or she has sole voting and investment power as to the shares of the Common Stock, except that, until a Common Stock purchase warrant or an Option is exercised, there is no voting right.

<Table>

<Caption>

NAME AND ADDRESS OF BENEFICIAL OWNER	NUMBER OF SHARES OF COMMON STOCK BENEFICIALLY OWNED	PERCENTAGE OF COMMON STOCK BENEFICIALLY OWNED(1)
-----	-----	-----
General Conference Corporation of Seventh-day Adventists.....	6,547,849(2)	20.4%
12501 Old Columbia Pike Silver Spring, MD 20804-6600		
Jonathan J. Pallin(3).....	3,185,589(4)	10.0%
722 Starlight Heights Drive La Canada, CA 91011		
Linda H. Masterson(5).....	1,776,370(6)	5.6%
1205 South Dupont Street Ontario, CA 91761		
Peter S. Gold(7).....	912,090(8)	2.9%
16027 Ventura Blvd., Suite 601 Encino, CA 91436		
Paul Sandler(7).....	216,011(9)	nil
533 West Hatcher Road Phoenix, Arizona 85021		
Charles J. Casamento(10).....	4,374(11)	0
99 Belbrook Way Atherton, CA 94027		
Stan Yakatan(10).....	4,374(11)	0
635 Euclid Avenue, Unit 110 Miami Beach, FL 33139		

</Table>

- (1) The percentages computed in this column of the table are based upon 31,570,853 shares of the Common Stock which were outstanding on the Record Date. Effect is given, pursuant to Rule 13d-3(1)(i) under the Exchange Act.

10